Artem Poltoratskiy

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i>-Mutant Advanced Non–Small Cell Lung Cancer

Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési et al. · JAMA · 2017 · 332 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Luis Paz‐Ares, Y Chen, Niels Reinmuth et al. · ESMO Open · 2022 · 321 citations · Full text

Medicine, Oncology, Pharmacology +12

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Chandra P. Belani, Nobuyuki Yamamoto, Artem Poltoratskiy et al. · BMC Cancer · 2014 · 69 citations · Full text

Medicine, Oncology, Pharmacology +14